Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: December 7, 2022

Details for Patent: 8,616,196

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,616,196 protect, and when does it expire?

Patent 8,616,196 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-five patent family members in twenty-two countries.

Summary for Patent: 8,616,196
Title:Inhalation device and a method for assembling said inhalation device
Abstract: An inhalation device for delivering doses of medicament to a user comprising: --a canister (5), said canister being adapted to accommodate the medicament to be dispensed to a user, and --a counter (15) which is connected to the canister (5). According to the invention --the canister (5) is adapted to receive the counter (15) on a base end (6a), --the counter and/or the canister further having contact parts (18, 20) for their attachment having means for increasing the friction and thereby allowing the counter to fixedly be attached onto the canister in a range of different positions in the lengthwise direction, --the counter further being adapted to during the process to assemble the counter to the canister, be urged onto the canister until the length of the counter and canister together is within a predefined tolerance of a predefined length.
Inventor(s): Hodson; Darren (Leicestershire, GB), Treneman; William (Cambridgeshire, GB)
Assignee: AstraZeneca AB (Sodertaije, SE)
Application Number:11/571,389
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Drugs Protected by US Patent 8,616,196

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-001 Jul 21, 2006 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,616,196

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0401773Jul 2, 2004
PCT Information
PCT FiledJune 23, 2005PCT Application Number:PCT/SE2005/000994
PCT Publication Date:January 12, 2006PCT Publication Number: WO2006/004496

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.